ArrowMark Colorado Holdings LLC Has $66.17 Million Stock Position in Certara, Inc. (NASDAQ:CERT)

ArrowMark Colorado Holdings LLC grew its holdings in Certara, Inc. (NASDAQ:CERT) by 164.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 6,213,278 shares of the company’s stock after acquiring an additional 3,861,674 shares during the quarter. ArrowMark Colorado Holdings LLC’s holdings in Certara were worth $66,171,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of CERT. Venturi Wealth Management LLC raised its stake in Certara by 839.1% in the 4th quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company’s stock worth $30,000 after purchasing an additional 2,509 shares in the last quarter. Wells Fargo & Company MN grew its position in shares of Certara by 48.4% during the 4th quarter. Wells Fargo & Company MN now owns 3,208 shares of the company’s stock worth $34,000 after purchasing an additional 1,047 shares in the last quarter. Johnson Financial Group Inc. bought a new position in shares of Certara during the fourth quarter worth approximately $47,000. Blue Trust Inc. raised its position in shares of Certara by 20.9% in the fourth quarter. Blue Trust Inc. now owns 4,747 shares of the company’s stock valued at $56,000 after buying an additional 822 shares in the last quarter. Finally, ANTIPODES PARTNERS Ltd boosted its stake in shares of Certara by 204.7% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 5,442 shares of the company’s stock valued at $58,000 after buying an additional 3,656 shares during the period. 73.96% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have commented on the company. William Blair restated a “market perform” rating on shares of Certara in a research note on Thursday, February 27th. TD Cowen began coverage on Certara in a research note on Thursday, February 27th. They issued a “buy” rating and a $16.00 price target for the company. KeyCorp increased their price objective on shares of Certara from $15.00 to $18.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 16th. Robert W. Baird boosted their target price on shares of Certara from $9.00 to $13.00 and gave the company a “neutral” rating in a research report on Friday, April 11th. Finally, Stephens reiterated an “overweight” rating and set a $17.00 price target on shares of Certara in a research report on Thursday, February 27th. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $15.17.

Certara Stock Down 2.3 %

Shares of NASDAQ CERT opened at $12.99 on Friday. The stock has a 50-day moving average price of $11.70 and a two-hundred day moving average price of $11.65. Certara, Inc. has a 12 month low of $8.64 and a 12 month high of $17.94. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. The company has a market cap of $2.10 billion, a price-to-earnings ratio of -64.95, a PEG ratio of 9.29 and a beta of 1.64.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.